In line with this, combination of PD1-IL2v with pembrolizumab did not provide any additional benefit in comparison to PD1-IL2v monotherapy, as 8 of 12 treated animals (66%) had a tumour smaller than 100 mm3 at experiment termination (Fig. 3h). This evidence concerns the gene PDCD1 and neoplasm.